Bepirovirsen: Clinical Trials

11 trials of Bepirovirsen, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

5 completed, 4 active not recruiting, 1 not yet recruiting, 1 terminated. 6 Phase 2, 4 Phase 1, 2 Phase 3.

By phase and status

Phase	Trials	Status
Phase 2	6	Active not recruiting 3, Completed 1, Not yet recruiting 1, Terminated 1
Phase 1	4	Completed 2, Active not recruiting 1, Terminated 1
Phase 3	2	Completed 2

Follow Bepirovirsen: new trials by email Literature Review of Bepirovirsen trials Research Report on Bepirovirsen

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Bepirovirsen Liver Biopsy Study Bepirovirsen, Liver biopsy, Optional Liver biopsy - HEPATITIS B CHRONIC, Hepatitis B Chronic Infection	Phase 2	Not yet recruiting	National University Health System, Singapore	30	2026-07-01	2026-07-10
A Study to Evaluate Blood Levels of Bepirovirsen in Adult Participants With Severe or Moderate Kidney Disease Bepirovirsen - Hepatitis B	Phase 1	Active not recruiting	GlaxoSmithKline	32	2025-09-26	2026-05-22
A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB) Daplusiran/Tomligisiran Dose Level 1, Daplusiran/Tomligisiran Dose Level 2, Bepirovirsen - Chronic Hepatitis B Virus Infection, Hepatitis B	Phase 2	Active not recruiting	GlaxoSmithKline	283	2024-11-11	2026-07-07
Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus) Bepirovirsen, Placebo - Hepatitis B	Phase 2	Active not recruiting	GlaxoSmithKline	153	2024-09-17	2026-07-08
Study to Evaluate the Effect of Bepirovirsen on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers Bepirovirsen, Placebo - Hepatitis B	Phase 1	Completed	GlaxoSmithKline	46	2024-07-18	2026-07-10
A Study to Evaluate the Relative Bioavailability of Subcutaneous Bepirovirsen When Delivered From a Vial or Prefilled Syringe Fitted With a Safety Syringe Device in Healthy Adult Participants Bepirovirsen - Hepatitis B	Phase 1	Completed	GlaxoSmithKline	160	2023-10-04	2025-07-18
Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1) Bepirovirsen, Placebo - Chronic Hepatitis B, Hepatitis B, Chronic	Phase 3	Completed	GlaxoSmithKline	981	2022-12-07	2026-07-08
Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2) Bepirovirsen, Placebo - Chronic Hepatitis B, Hepatitis B, Chronic	Phase 3	Completed	GlaxoSmithKline	857	2022-12-06	2026-07-08
Study of GSK3965193 in Healthy Participants and Participants Living With Chronic Hepatitis B Infection GSK3965193, Placebo to match GSK3965193, Bepirovirsen - Hepatitis B	Phase 1 / Phase 2	Terminated	GlaxoSmithKline	74	2022-04-14	2026-10-14
A Study on the Safety, Efficacy and Immune Response Following Sequential Treatment With an Anti-sense Oligonucleotide Against Chronic Hepatitis B (CHB) and Chronic Hepatitis B Targeted Immunotherapy (CHB-TI) in CHB Patients Receiving Nucleos(t)Ide Analogue (NA) Therapy GSK3228836, GSK3528869A, Control - Hepatitis B, Chronic	Phase 2	Completed	GlaxoSmithKline	174	2022-03-22	2025-12-30
Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure) Bepirovirsen, Placebo - Hepatitis B	Phase 2	Active not recruiting	GlaxoSmithKline	360	2021-12-14	2026-06-24

Conditions studied

Sponsors

Countries

Top investigators

Results publications

NIH funding